Turing Won’t Cut Price of Daraprim, Will Instead Offer Discount Program
Turing Pharmaceuticals has flip-flopped on its decision to reduce the list price of Daraprim, instead offering discounts of up to 50 percent to hospitals, as well as other minor adjustments to help patients afford the drug, which has skyrocketed in price from $13.50 a pill to $750.
In addition to the discount, in early 2016, the company will provide smaller, 30 tablet bottles. That action is designed to make it easier for hospitals to stock the drug and lower carrying costs. Turing also says it would provide free sample starter packs to physicians to ensure they have immediate access to start therapy in emergency situations.
Further, the firm says it would participate in Medicaid and the Section 340B discount program. It adds that patients with commercial insurance would not have to pay more than $10 per prescription out-of-pocket as long as Turing’s co-pay program is used. The company says it will provide the drug for free to uninsured, qualified patients at or below 500% of the federal poverty level.
After public outcry in September, Turing CEO and founder Martin Shkreli says he would cut the price of the toxoplasmosis medication (DID, Sept. 24). — Kellen Owings
Subscribe to Drug Industry Daily and save $300 off the regular one-year price of $1,695 — plus receive a FREE copy of our webinar CD, Talking About Your Product Pipeline: How FDA and SEC Regulate Life Sciences Communications — a $287 Value!
LINKS TO KEY DOCUMENTS — You get links to key documents that support DID's articles such as draft and final guidances, 483s and warning letters, proposed rules, closeout letter, full text of proposed legislation and GAO reports.
ONLINE ACCESS — Consider our newsletter archive your personal library! Search your current issue — and hundreds of past issues — by keyword and relevancy.
Copyright ©2019. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing